Stopping cervical cancer in its tracks with earlier detection
Bringing four colposcopes – state-of-the-art cervical cancer detection technology – to the QEII Health Sciences Centre.
A COMMUNITY RALLIES
As part of our We Are campaign, QEII Foundation donors and our BMO Ride for Cancer community came together to raise $400,000 to fully fund critical cervical cancer diagnostic and treatment equipment aimed at better detecting and treating precancerous cells. With up to 200 Atlantic Canadian patients visiting the QEII’s colposcopy clinic each week, the impact of this equipment is beyond measure.
Dr. Katharina Kieser, division head for QEII Gynecologic Oncology, looks through a new donor-funded colposcope which helps diagnose abnormal cells in the cervix – ultimately protecting women against deadly cancers.
HOW IT WORKS
A colposcope is a minimally-invasive tool that helps diagnose and prevent cervical cancer and treat precancerous cell changes before they develop into cancer. As cervical cancer is the third most common type of cancer among women, this technology plays a key role in earlier detection and prevention.
Thanks to four new colposcopes funded by our donors and BMO Ride for Cancer community, care teams now have access to exceptional image quality, enhancing exams and making it easier to detect and treat precancerous cells through LEEP (Loop Electrosurgical Excision Procedure), which removes abnormal cells from the cervix. This equipment also improves the colposcopy experience for patients by providing high-definition imaging, helping them understand the procedure and the potential outcomes of their exams.
The result? Up to 200 patients directly impacted each week and ultimately keeping more women out of the QEII Cancer Centre by stopping the disease in its tracks.
Members of the QEII’s colposcopy clinic with one of four colposcopes funded by donors.
